Esperion Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Esperion Therapeutics, Inc.
In its third annual report on fair access to prescription drugs, the US pricing watchdog found high concordance with some of its recommended policies, but thinks greater transparency is needed for a thorough assessment.
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.
The drug maker announced the start of a Phase III program for its oral PCSK9 inhibitor MK-0616, including a 14,550-patient outcomes trial set to start later in the year.
The company plans to ramp up its commercial infrastructure later this year, ahead of a labeling update based on positive cardiovascular outcomes trial data.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.